

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 2, 2016
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:20 p.m. on Wednesday, November 2, 2016.

2. Welcome

Thomas Phillips, RPh, called the meeting to order and welcomed members, guests, and staff members.

Mr. Phillips opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Joni Bollinger, MD
Philip Mubarak, MD

Tan Platt, MD
Gregory Browning, MD

Cheryl Hartvigsen, R.Ph.
Thomas Phillips, R.Ph.

SC DHHS Staff:

Bryan Amick, PharmD, MBA
Jim Bradford, MD
Janet Giles

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, September 28, 2016

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
AstraZeneca	S. Bobby Arelli, MD	GI Motility, Chronic
NovoNordisk	Carolyn Bethea, MS, RD	GLP1 Inhibitors

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Class for Review

- GI Motility, Chronic
- Immunomodulators, Topical
- Rosacea (Topical)

Classes for Re-Review

- Beta Adrenergic Long-Acting Inhalers
- GLP1 Inhibitors

The chart below represents the recommendations from the P & T Committee:

GI MOTILITY, CHRONIC	
Preferred	Non-Preferred
Amitiza [®] Linzess [®]	Lotronex [®] Movantik [®] Relistor [®] Viberzi [®]

IMMUNOMODULATORS, TOPICAL	
Preferred	Non-Preferred
Aldara [™]	Imiquimod Zyclara [®]

ROSACEA (TOPICAL)	
Preferred	Non-Preferred
Finacea [®] (<i>azelaic acid gel/foam</i>) MetroGel [®] MetroLotion [®] MetroCream [®]	Metronidazole (cream, gel, lotion) Mirvaso [®] Noritate [™] Rosadan [™] Soolantra [®]

BETA ADRENERGIC LONG-ACTING INHALERS	
Preferred Serevent™ Diskus™	Non-Preferred Arcapta™ Neohaler™ Striverdi® Respimat®

GLP1 INHIBITORS	
Preferred Bydureon® Victoza®	Non-Preferred Byetta® Tanzeum™ Trulicity®

5. **Old Business**

None

6. **New Business**

None

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Class for Review

GI Motility, Chronic
Immunomodulators, Topical
Rosacea (Topical)

Classes for Re-Review

Beta Adrenergic Long-Acting Inhalers
GLP1 Inhibitors

8. **Closing Comments**

The next meeting is "To Be Determined".

9. **Adjournment**

The meeting adjourned at 5:10 p.m.